• Health & Medicine

Glitzy cigarette packs entice kids to start deadly addiction

A new study reveals for the first time that glitzy and glamorous cigarette packaging makes children susceptible to smoking. A new study reveals for the first time that glitzy and glamorous cigarette packaging makes children susceptible to smoking.

27 September 2013

• Health & Medicine

Crucial tobacco vote in the European Parliament looms

As a major vote in the European parliament about tobacco products looms, we look at what MEPs will be voting on and what this could mean for tobacco marketing. As a major vote in the European parliament about tobacco products looms, we look at what MEPs will be voting on and what this could mean for tobacco marketing.

25 September 2013

• Health & Medicine

Emma Griffin appointed new Chair of the board for Cancer Research UK’s Catalyst Club

Cancer Research UK announced today that Emma Griffin will be assuming the role of Chair of the Board for Cancer Research UK's Catalyst Club with immediate effect. Cancer Research UK announced today that Emma Griffin will be assuming the role of Chair of the Board for Cancer Research UK's Catalyst Club with immediate effect.

25 September 2013

CRT Pioneer fund, BACIT and SAREUM enter agreement to fund development of drugs to treat cancers including pancreatic, bowel and lung

The funding will enable the project to move swiftly towards, and potentially into Phase I clinical trials. The funding will enable the project to move swiftly towards, and potentially into Phase I clinical trials.

24 September 2013

• Science & Technology

Doing the twist on damaged DNA – Simon Boulton wins the Paul Marks cancer research prize

Cancer Research UK scientist Dr Simon Boulton has won a prestigious award for his research - we chatted with him about his current work and future goals. Cancer Research UK scientist Dr Simon Boulton has won a prestigious award for his research - we chatted with him about his current work and future goals.

23 September 2013

Paul Marks Prize 2013 awarded to Cancer Research UK scientist

Dr Simon Boulton has been named as one of the recipients of the 2013 Paul Marks Prize for cancer research from the Memorial Sloan-Kettering Cancer Center in America. Dr Simon Boulton has been named as one of the recipients of the 2013 Paul Marks Prize for cancer research from the Memorial Sloan-Kettering Cancer Center in America.

23 September 2013

• Science & Technology
• Health & Medicine

News digest – radiotherapy for breast cancer, nuclear power plants, zebrafish and more

This week's pick of the cancer headlines include news about radiotherapy doses and breast cancer, leukaemia and nuclear power plants, plus zebrafish and more. This week's pick of the cancer headlines include news about radiotherapy doses and breast cancer, leukaemia and nuclear power plants, plus zebrafish and more.

21 September 2013

• Health & Medicine

Less is more for radiotherapy in early breast cancers

Giving radiotherapy in fewer, larger treatments is at least as safe and effective at treating early breast cancer as the international standard dose. Giving radiotherapy in fewer, larger treatments is at least as safe and effective at treating early breast cancer as the international standard dose.

19 September 2013

• Health & Medicine

Proton therapy is coming to the UK, but what does it mean for patients?

Radiotherapy is a vital cancer treatment and proton beam therapy could help deliver radiotherapy in a more precise way - find out more about the benefits. Radiotherapy is a vital cancer treatment and proton beam therapy could help deliver radiotherapy in a more precise way - find out more about the benefits.

16 September 2013

Cancer Research Technology and Teva Pharmaceuticals form R&D alliance for R&D DNA damage response drugs

Cancer Research Technology Ltd. (CRT), Cancer Research UK’s technology development arm, and Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) have signed a multi-project alliance agreement to research and develop first-in-class cancer drugs that modulate DNA damage and repair response (DDR) processes in cancer cells. Cancer Research Technology Ltd. (CRT), Cancer Research UK’s technology development arm, and Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) have signed a multi-project alliance agreement to research and develop first-in-class cancer drugs that modulate DNA damage and repair response (DDR) processes in cancer cells.

16 September 2013

• Science & Technology
• Health & Medicine

News digest – e-cigarettes, childhood leukaemia, skin implants and more

Here's our pick of the week's cancer news, including e-cigarettes, a rare genetic link to childhood leukaemia, cancer-targeting skin implants and more. Here's our pick of the week's cancer news, including e-cigarettes, a rare genetic link to childhood leukaemia, cancer-targeting skin implants and more.

14 September 2013